CYCN Stock Summary and Trading Ideas (Cyclerion Therapeutics | NASDAQ:CYCN)

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.

Cyclerion Therapeutics trades on the NASDAQ stock market under the symbol CYCN.

As of April 24, 2026, CYCN stock price declined to $2.94 with 142,604 million shares trading.

CYCN has a beta of 1.36, meaning it tends to be more sensitive to market movements. CYCN has a correlation of 0.01 to the broad based SPY ETF.

CYCN has a market cap of $11.19 million. This is considered a Sub-Micro Cap stock.

Last quarter Cyclerion Therapeutics reported $1 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $925,000 and exceeded earnings estimates by $.19.

In the last 3 years, CYCN traded as high as $9.47 and as low as $1.03.

The top ETF exchange traded funds that CYCN belongs to (by Net Assets): ONEQ, VXF.

CYCN has underperformed the market in the last year with a price return of -2.3% while the SPY ETF gained +31.9%. However, in the short term, CYCN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +90.9% vs +3.8% return in SPY. But in the last 2 weeks, CYCN shares have been beat by the market, returning +1.0% compared to an SPY return of +5.1%.

CYCN support price is $2.66 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYCN shares will trade within this expected range on the day.